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ABSTRACT 
Background: The purpose of this study was to analyze optical coherence tomography (OCT) parameters of the choroid and 
retina in subjects with pre-manifest and manifest Huntington's disease (HD). 
Methods: In this case-control study, the retinal parameters of patients with genetically confirmed HD and healthy controls 
were evaluated using spectral-domain optical coherence tomography (SD-OCT). Genetic and neurological assessments were 
performed besides a thorough ophthalmological examination. Contrast Sensitivity (CS) logarithm was evaluated using the 
Freiburg Vision Test. The association between OCT parameters and clinical and genetic characteristics was studied. 
Results: A total of 91 subjects, including 60 HD subjects (60 eyes) and 31 control subjects (31 eyes) were eligible according to the 
inclusion and exclusion criteria. The range of the CAG (cytosine-adenine-guanine) repeat expansion size was 38–56 repeats, the mean 
± standard deviation (SD) of the Unified HD Rating Scale (UHDRS) motor scores was 36.3±29.7, and disease duration was 13.7±7.2 years 
in HD subjects. Compared to the control group, significant decreases in the mean ganglion cell complex thickness and mean, temporal, 
superior, inferior, and nasal retinal nerve fiber layer (RNFL) thickness in HD subjects was revealed in OCT examination (P-values < 0.001, 
< 0.001, < 0.001, 0.023, 0.007 and 0.014, respectively). An inverse correlation between the disease duration and the mean RNFL 
thickness (r =- 0.470, P = 0.002) was found. 
Conclusions: Localization of retinal thickness loss shows a specific pattern of retinal neurodegeneration in HD, similar to 
Parkinson’s disease and mitochondrial diseases. The association with the disease duration confirms the progressive nature of 
these changes. 
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INTRODUCTION 
The ability to use the retina as a "window" to the central 
nervous system has attracted special attention in recent years 
[1]. Retinal optical coherence tomography (OCT) parameters 
are considered potential biomarkers of several neurological 
diseases, such as multiple sclerosis, neuromyelitis optica, 
Alzheimer's disease, and Parkinson's disease (PD) [2–4]. In a 
recent longitudinal study, the sensitivity of the prognostic 
value of retinal OCT in the discrimination of preclinical stages 
of Alzheimer's disease was 87% [5].  
Huntington's disease (HD) is a steadily progressing, fully 
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inherited cytosine-adenine-guanine (CAG) trinucleotide repeat 
expansion in the huntingtin gene [6].  
The prevalence of the disease in the Caucasian race is 4.64-
13.7 per 100/000 [7-10]. The pre-manifest and manifest stages 
can be distinguished in the development of the disease [11-
13], and the age at the time of motor clinical onset correlates 
with the number of CAG repeats [13, 14]. The monogenic 
nature of inheritance, high penetrance, and the exceptional 
possibility of monitoring patients at the asymptomatic stage of 
the disease let us to consider HD as an exceptional «model» 
disease for studying the early stages of sporadic 
neurodegenerative diseases [15] for a thorough investigation 
of the retina and the choroid in pre-manifest and manifest HD 
[15]. The first study on retinal OCT in HD was announced in 
2014 [16], showing peripapillary retinal nerve fiber layer (RNFL) 
degeneration. Kersten et al. [17], Andrade et al. [18], Sevim et 
al. [19], Gatto et al. [20], and Di Maio et al. [21] presented a 
comprehensive analysis of retinal OCT parameters in groups of 
8, 26, 15, 14, and 16 HD patients, respectively. Kersten et al. 
established peripapillary RNFL thinning in the temporal 
quadrant [17], Gatto et al. observed temporal and superior 
thinning RNFL [20], and Gulmes et al. showed thinning of the 
inner retinal layer in HD [19]. However, Andrade et al. found 
no changes in RNFL thickness; they observed only macular 
choroidal thickness loss [18], which was partly confirmed by Di 
Maio [21].  
The small group volume and insufficient data on pre-manifest 
HD require further research. We aimed to analyze OCT 
parameters of choroid and retina in subjects with pre-manifest 
and manifest HD, and compare them to the control group. 
METHODS 
A case-control study was performed between January 2016 
and December 2019. All HD subjects were genetically 
confirmed. Healthy volunteers were recruited from the control 
group. The study was approved by the Institutional Ethical 
Committee of Privolzhsky Research Medical University, Nizhny 
Novgorod, Russian Federation. The study adhered to the 
principles of the Declaration of Helsinki. All participants 
provided informed consent before participating in the study. 
Genetic and neurological assessments were performed as 
follows: CAG repeat length in the huntingtin gene was 
evaluated in the HD group (by the Center for Molecular 
Genetics, Moscow, Russia). A neurological examination was 
performed by a specialist at the Neurology Department of 
Privolzhsky Research Medical University, Nizhny Novgorod, 
Russian Federation. Disease duration, Unified Huntington's 
Disease Rating Scale (UHDRS) motor scores, and disease stage 
was determined. The control subjects’ assessment included a 
family history taking and neurological examination, together 
with an evaluation of cognitive function using the Mini-Mental 
State Examination (MMSE) scale [5]. 
A thorough ophthalmological examination was performed at 
the Ophthalmology Department of the Volga District Medical 
Center of the Federal Medical and Biological Agency of Russia. 
Complete medical history was recorded. Best-corrected visual 
acuity (BCVA), intraocular pressure (IOP) measurement with 
Goldmann tonometry, biomicroscopy, and indirect 
ophthalmoscopy with aspherical lenses after pupil dilation 
were performed in all groups. Contrast Sensitivity (CS) 
logarithm was evaluated using the Freiburg Vision Test 
(‘FrACT’, Version 3.8.1) from a 200 cm distance [22]. Spectral-
domain optical coherence tomography (RTVue-100 spectral-
domain OCT; Optovue Inc., Fremont, CA, USA) was used. All 
scans were performed during the day (from 12 to 2 p.m). The 
choroid thickness in the central fovea was measured manually 
on the vertical and horizontal retinal scans obtained with the 
cross-line mode and then the mean value was calculated. The 
peripapillary RNFL thickness within a diameter of 3.46 
millimeters (mm) was assessed using the optic nerve head 
(ONH) and 3-dimensional optic disk assessment (3D Disc) 
(RNFL Thickness Analysis) protocols. The mean thickness of the 
four quadrants was analyzed. The ganglion cell complex (GCC) 
includes; the RNFL, ganglion cell layer, and inner plexiform 
layer. The mean GCC thickness was evaluated using the GCC 
protocol. As the GCC protocol provides no quantitative 
information concerning GCC thickness in parafovea and 
perifovea, we attempted to classify these changes effectively 
using the significance map. We differentiated parafoveal GCC 
loss, perifoveal arcuate thinning, and nonspecific changes. 
Scans obtained with a signal strength index (SSI) of less than 50 
or in the presence of artifacts (saccades, incorrect focusing of 
the device at the center of the optic nerve head, etc.) were 
excluded from the study. Ophthalmological and OCT 
examinations were performed by an ophthalmologist. 
Ophthalmic exclusion criteria were; BCVA below 0.9 (decimal), 
spherical or astigmatic refractive errors above 3 diopters, IOP 
greater than 21 mm of mercury (mmHg) or the difference 
between the eyes more than 2 mmHg, the vertical cup to disc 
ratio of more than 0.4 (according to the OCT), any significant 
optical media opacity, previous ocular trauma or surgery 
(including laser), any coexisting ocular diseases, and the use of 
eye drops (except for lubricants).  
Neurological and other exclusion criteria for the control group 
were an MMSE score of less than 26, positive family history in 
terms of neurodegenerative diseases and any significant 
neurological abnormality found during the neurological 
examination, age below 18 or older than 59 years, previous 
head trauma, diabetes, arterial hypertension, ischemic heart 
disease, and other systemic diseases with potential damage to 
the eyes and chronic alcohol or hormonal use. Participants 
were advised to avoid any physical activity and caffeine-
containing drinks two hours before the examination. Those 
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with a systolic blood pressure beyond 125 mmHg or diastolic 
blood pressure beyond 85 mmHg at the beginning of the 
survey were also excluded. Data were analyzed using the IBM 
Statistical Package for Social Sciences (SPSS) Statistics for 
Windows, version 22 (IBM Corp., Armonk, N.Y., USA) 
Continuous variables were presented as arithmetic mean ± 
standard deviation (SD). The normality of the data distribution 
was verified using the Shapiro-Wilk test. Student's t-test for 
independent samples was used for samples with a normal 
distribution. ANOVA was used as appropriate. Categorical 
variables (sex) were compared using the chi-square test. The 
association between OCT parameters and clinical and genetic 
characteristics was studied using Pearson’s correlation. The 
accepted significance level was set at 5% (P < 0.05). There was 
a correlation between the right and left eye parameters; 
therefore, the analysis was performed for the right eye of each 
subject. 
RESULTS  
A total of 91 subjects, including 60 HD subjects (60 eyes) and 
31 control subjects (31 eyes) were eligible according to the 
inclusion and exclusion criteria. In the HD group, there were 29 
pre-manifest and 31 manifest patients. The CAG repeat length 
varied from 38 to 56 (mean ± SD; 44.3 ± 3.8), the mean ± SD of 
UHDRS motor scores in the manifest patients was 36.3 ± 29.7, 
and the mean ± SD of disease duration was 13.7 ± 7.2 years. 
Differences in age, sex, BCVA, and IOP between the case and 
control groups were not significant (P = 0.90, 0.599, 0.26, and 
0.945, respectively) (Table 1). The manifest patients were older 
than the pre-manifested subjects (P < 0.001), which is 
explained by the sequential development of the stages of the 
disease. The CS logarithm was significantly lower in both pre-
manifest (P = 0.002) and manifest (P < 0.001) HD subjects 
compared to the controls.  
The pre-manifest HD subjects showed a significantly lower 
thickness of the subfoveal choroid (P = 0.006), mean GCC (P < 
0.001), mean RNFL thickness (P = 0.002), and temporal RNFL 
thickness (P < 0.001) compared to the controls. In addition to 
having significantly lower values for these parameters (P < 
0.001), the manifest HD patients also had lower nasal (P = 
0.033) and inferior RNFL thickness (P = 0.010) compared to 
controls (Table 2). GCC scans could be unambiguously 
classified as parafoveal GCC loss in 16 HD patients, including 13 
manifest and 3 pre-manifest subjects (Figure 1). There were no 
scans with signs of perifoveal arcuate thinning. Subfoveal 
choroidal thickness was negatively correlated with disease 
duration (r = -0.62, P < 0.001). The mean GCC thickness (r= -
0.66, P = 0.003) and temporal RNFL thickness (r = -0.59, P = 
0.010) were negatively correlated with the UHDRS motor 
score. A significant but mild association (r < 0.50, P < 0.05) was 
found between structural parameters, including subfoveal 
choroidal thickness, mean GCC, and mean RNFL thickness with 
CAG repeat length, as well as, between mean GCC, and mean 
RNFL thickness with disease duration (Table 3). However, there 
was no significant correlation between CS logarithm and OCT 
parameters.
 
Table 1: Baseline characteristics of the study participants. 
Parameter All HD subjects (n=60) 
Mean ± SD  
Pre-manifest HD (n=29) 
Mean ± SD  
Manifest HD (n=31) 
Mean ± SD  
Controls (n=31) 
Mean ± SD  
P-value* HD vs. controls 
Age (years) 37.6±10.2 30.63±4.62 42.60±10.20 37.3±10.8 0.90 
BCVA; decimal 1.0±0.0 1.0±0.0 1.0±0.0 1.0±0.1 0.26 
Log CS 1.712±0.210 1.785±0.166 1.646±0.227 2.005±0.141 <0.001 
IOP; mm Hg 19.3±1.7 18.9±1.4 19.5±1.8 19.3±1.5 0.945 
Abbreviations: HD, Huntington's disease; n, number; SD, standard deviation; log CS, contrast sensitivity logarithm; BCVA, best-corrected visual acuity; 
IOP, intraocular pressure; mmHg, millimeter of mercury; vs, versus. * - t-test significance (Chi-square test for sex), P < 0.05 is shown in bold 
 
 
Table 2: Retinal and choroidal thickness parameters in the study participants. 
Parameter (μm) Pre-manifest HD (n=29) 
Mean±SD 





All HD vs. CS⃰  
P-value Pre-
manifest HD vs. CS 
P-value Manifest 
HD vs. CS 
Subfoveal choroid 262.6±50.5 239.7±25.5 315.1±74.1 <0.001  0.006  <0.001  
Mean GCC  85.36±6.43 84.70±8.66 93.8±5.2 <0.001  <0.001  <0.001  
Mean RNFLT 99.86±8.74 93.74±8.96 105.7±7.5 <0.001  0.002  <0.001  
Temporal RNFLT 69.29±12.41 69.44±16.67 86.8±6.9 <0.001  <0.001  <0.001  
Superior RNFLT 122.14±12.50 109.86±15.31 119.5±14.4 0.023  1.0 0.076 
Nasal RNFLT 76.43±7.62 71.86±11.65 80.5±12.9 0.014  0.051 0.033  
Inferior RNFLT 133.64±15.39 125.32±14.74 138.7±18.0 0.007  0.075 0.010  
Abbreviations: µm, micrometer; n, number; SD, standard deviation; HD, Huntington's disease; CS, control subjects; GCC, ganglion cell complex; RNFLT, 
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Table 3: Correlation Between Structural Parameters and Markers of Disease Progression in Patients With HD. 
Parameter (μm) CAG repeat length Disease duration (Y) UHDRS Motor Score Log CS 
 r P-value r P-value r P-value r P-value 
Subfoveal choroid thickness -0.342 0.031 -0.619 <0.001 -0.041 0.871 -0.078 0.758 
mean GCC -0.487 0.001 -0.440 0.003 -0.657 0.003 -0.199 0.201 
mean RNFLT -0.389 0.014 -0.470 0.002 -0.433 0.082 -0.093 0.558 
Temporal RNFLT -0.134 0.409 -0.110 0.483 -0.590 0.010 0.238 0.124 
Abbreviations: HD, Huntington's disease; µm, micrometer; Y, years; GCC, ganglion cell complex; RNFLT, retinal nerve fiber layer thickness; log CS, contrast 
sensitivity logarithm; UHDRS, Unified Huntington's Disease Rating Scale; CAG, cytosine-adenine-guanine. P < 0.05 is shown in bold
 
 
Figure 1: Sample Ganglion cell complex (GCC) significance maps of the 
subjects; A: The left eye of the control subject, 25 years old, having no 
abnormalities; B: The left eye of the pre-manifest Huntington's disease 
(HD) subject, 25 years old, showing slight parafoveal degeneration; C: 
The left eye of the manifest HD subject, 41 years old, having marked 




The main finding of this study was a specific parvocellular 
pattern of retinal neurodegeneration characterized by 
parafoveal GCC thinning and predominantly temporal 
RNFL loss in both pre-manifest and manifest HD subjects 
(Figure 1). Less pronounced but significant RNFL thickness 
reduction in the nasal and inferior quadrants was 
described in the manifest HD patients for the first time. 
GCC degeneration and temporal RNFL thinning were 
associated with increased UHDRS motor scores. Macular 
choroid atrophy correlated with disease duration, and 
CAG repeat length showed a mild inverse association with 
some OCT parameters. Nevertheless, previous studies 
have shown that CS loss [23] did not have any correlation 
with OCT parameters. 
The study of retinal structures in neurodegenerative 
diseases has been performed by various teams since 2004 
[24]. There has been a growing interest to study the 
choroid structure in the last few years because it consists 
of the end branches of the internal carotid artery that 
feeds the structures of the brain. A thinning macular 
choroid has been described in Alzheimer's disease [25] 
and PD [26], while peripapillary choroid was thickened in 
PD [21]. The choroid macular thinning in HD was detected 
by Andrade et al. for the first time while the peripapillary 
choroid did not show any significant changes [18]. Di Maio 
claimed that central choroidal thickness was slightly 
thinner in HD patients than in the controls, and observed 
no difference in retinal and choriocapillaris vessel density 
[21]. We aimed to prove these findings in a larger and 
more heterogeneous clinical sample. Our results are very 
similar to those of Andrade et al. [18]. The choroid is a 
dynamic structure, its thickness is determined both by 
functional state and structural remodeling [27, 28]. 
Thinning of the macular choroid in HD can be considered 
a consequence of intracranial hemodynamic disturbances, 
probably associated with abnormal huntingtin 
accumulation in the cerebral vessels [29]. 
 
  
Med Hypothesis Discov Innov Optom. 2020; 1(1) 
  
22 EARLY RETINAL DEGENERATION IN HUNTINGTON'S DISEASE BASED ON OCT 
 
 
Ganglion cells are third-order neurons of the visual 
analyzer; their axons go in the RNFL and compose the 
optic nerve. Thinning of GCC and RNFL have been 
described in Alzheimer's [3, 30] and PD [31]. According to 
a meta-analysis of 887 patients with Alzheimer's disease, 
the most pronounced RNFL reduction was detected in the 
upper and lower quadrants related to the magnocellular 
system [32]. A similar pattern of retinal degeneration has 
been noted in glaucoma [33, 34], and similarities in the 
pathogenesis of Alzheimer's disease and glaucoma have 
been previously reported [35, 36]. The results of RNFL 
assessment in PD indicate a preferential temporal RNFL 
reduction [23, 26, 31, 35], which is more consistent with 
optic nerve atrophy in mitochondrial diseases, such as 
Leber's hereditary optic neuropathy [37]. According to the 
similarity of the pathogenesis of PD and HD, La Morgia et 
al. suggested that the development of optic neuropathy in 
HD should have a parvocellular pattern compared to 
Alzheimer's disease and glaucoma [38]. However, 
previous visual functional studies have revealed different 
findings in patients with HD. O'Donnell et al. assumed a 
major lesion of the magnocellular pathway [39], while a 
recent study [23] showed early dysfunction of the 
parvocellular pathway, which is consistent with the results 
of the current study. 
Our data support the hypothesis of La Morgia et al. [38] 
according to parafoveal GCC degeneration with the most 
pronounced temporal RNFL loss in both pre -and manifest 
HD subjects, this is in accordance with the results of 
Kersten et al. and Gatto et al. [17, 20]. This phenomenon 
could be explained by mitochondrial dysfunction in HD 
[17, 40], causing the death of the most energy-consuming 
cells, in particular, ganglion cells [41], which is consistent 
with experimental data suggesting an earlier lesion of 
cones than rods in the course of HD progression [42]. At 
the same time, less pronounced but significant RNFL 
thinning in the nasal and inferior quadrants tends to 
progress at the manifest stage, indicating that retinal 
neurodegeneration is not restricted to the parvocellular 
pathway only but involves the magnocellular pathway as 
well in the manifest stage. 
This study had some limitations. The major one was its 
cross-sectional design, with no data on the retinal 
degeneration progression rate. Subjective manual choroid 
thickness assessment suggests a higher risk of bias than 
computer analysis in more recent OCT devices [43]. In 
addition, axial eye length was not considered, but the 
refraction was considered [44]. Nevertheless, our data on 
choroid thickness were consistent with some previous 
results [18], obtained using a standard protocol. The visual 
function assessment consisted of visual acuity and CS tests 
that showed no significant correlation with OCT data; 
therefore, further research is required. 
However, the current study also has some strengths. 
There were 60 genetically confirmed clinically 
heterogeneous HD subjects who were compared with the 
healthy control group. The main factors affecting OCT 
results included patients’ health issues, functional states, 
and image artifacts [45–47]. As a result, we attempted to 
add new findings to an extremely insufficient 
understanding of visual dysfunction in HD [48]. The 
association between OCT parameters and visual functions, 
including quantitative examination of color sensitivity in 
HD and the course of retinal degeneration as part of a 
prospective study, requires further research. It is also 
critical to identify the link between retinal dysfunction and 
mitochondrial biogenesis in HD. 
 
CONCLUSIONS 
An interdisciplinary approach used in the diagnosis and 
monitoring of neurodegenerative diseases using new 
noninvasive biomarkers is necessary. Our results 
confirmed that macular choroidatrophy, ganglion cells, 
and axon degeneration start early in the course of the 
disease. Ganglion cells and RNFL thinning have a specific 
pattern of preferential parvocellular degeneration, which 
is probably associated with mitochondrial dysfunction. 
Clinical deterioration at the manifest stage of HD is 
accompanied by progressive retinal and choroid 
degeneration, yet, CAG repeat length has a mild 
correlation with some OCT parameters.  
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